How does our DC based technology activate your immune response?
CoImmune’s proprietary technology creates individualized immunotherapies that harness and reprogram dendritic cells to target antigens specific to each person’s disease. Each patients’ tumor is unique to each individual. Mutations or neoantigens in the tumor or over-expression of normal proteins can lead to malignant growth. Finding the right antigen is a challenge and has confounded many prior immuno-oncology strategies.
The scientists at CoImmune have overcome this challenge by taking advantage of the special place dendritic cells hold as master regulators of the immune system. We have engineered these cells to capture the spectrum of neoantigens and variant antigens that are specific to each patient’s individual disease. We designed these cells to overcome immunosuppression by enabling specifically targeted, durable memory T-cells.
Our process uses only a small disease sample or biopsy as the source of disease-specific antigens, and the patient’s own dendritic cells, which are optimized from cells collected by a leukapheresis procedure. Our proprietary process uses RNA isolated from the patient’s disease sample to program dendritic cells to target disease-specific antigens. These activated, antigen-loaded dendritic cells are then formulated with the patient’s plasma and administered via intradermal injection as an individualized immunotherapy.
CoImmune scientists have recognized that single therapeutic approaches have had only limited clinical success. Therefore, we have innovated a precise immunotherapeutic approach unlike any other with the potential to be revolutionary. This platform technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases. Our GMP manufacturing process is specifically designed to overcome many of the manufacturing and commercialization challenges that have impeded other cellular immunotherapies. Given the uniqueness of the technology and a strong safety profile we are well positioned to combine with other immuno-oncology agents.